<!doctype html>


<html class="no-js" dir="ltr" lang="en" xmlns="http://www.w3.org/1999/xhtml">


<!-- Mirrored from www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/compliance-enforcement/notice-stakeholders-release-guidance-documents-consultation-various-good-manufacturing-practices-drug-establishment-licensing-guidance-documents.html by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 03 Apr 2025 21:44:47 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head prefix="og: http://ogp.me/ns#">
    
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
<meta charset="utf-8"/>
<title>Notice to Stakeholders –Release of Guidance Documents for Consultation: Various good manufacturing practices and drug establishment licensing guidance documents - Canada.ca</title>
<meta content="width=device-width,initial-scale=1" name="viewport"/>


	<link rel="schema.dcterms" href="http://purl.org/dc/terms/"/>
	<link rel="canonical" href="notice-stakeholders-release-guidance-documents-consultation-various-good-manufacturing-practi"/>
    <link rel="alternate" hreflang="en" href="notice-stakeholders-release-guidance-documents-consultation-various-good-manufacturing-practi"/>
	
        <link rel="alternate" hreflang="fr" href="https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/participation-public-consultations/conformite-application-loi/avis-intervenants-publication-documents-orientation-fins-consultation-divers-documents-orientation-bonnes-pratiques-fabrication-octroi-licences.html"/>
	
	
		<meta name="description" content="Health Canada is pleased to announce the release of the following draft guidance documents for a 90 day stakeholder consultation from January 18, 2017 to April 18, 2017: GUI-0001: Good manufacturing practices guide for drug products; GUI-0023: Risk classification guide for drug good manufacturing practices observations; GUI-0031: Good manufacturing practices for medical gases; GUI-0080: How to demonstrate foreign building compliance with drug good manufacturing practices; GUI-0119: Annex 1 to the Good manufacturing practices guide - Manufacture of sterile drugs."/>
	
	
		<meta name="keywords" content="public consultations, Consultation, Survey, ICH Q7 Constituencies, Input for Development of a Question and Answer Document, Implementation Working Group, IWG, International Conference on Harmonization Steering Committee, guideline, harmonize expectations during inspections, small molecules, biotech Active Pharmaceutical Ingredients, APIs"/>
	
	
		<meta name="author" content="Health Canada"/>
	
	
		<meta name="dcterms.title" content="Notice to Stakeholders –Release of Guidance Documents for Consultation: Various good manufacturing practices and drug establishment licensing guidance documents"/>
	
	
		<meta name="dcterms.description" content="Health Canada is pleased to announce the release of the following draft guidance documents for a 90 day stakeholder consultation from January 18, 2017 to April 18, 2017: GUI-0001: Good manufacturing practices guide for drug products; GUI-0023: Risk classification guide for drug good manufacturing practices observations; GUI-0031: Good manufacturing practices for medical gases; GUI-0080: How to demonstrate foreign building compliance with drug good manufacturing practices; GUI-0119: Annex 1 to the Good manufacturing practices guide - Manufacture of sterile drugs."/>
	
	
		<meta name="dcterms.creator" content="Health Canada"/>
	
	
	
		<meta name="dcterms.language" title="ISO639-2/T" content="eng"/>
	
	
		<meta name="dcterms.subject" title="gccore" content="Health and Safety"/>
	
	
		<meta name="dcterms.issued" title="W3CDTF" content="2017-01-18"/>
	
	
		<meta name="dcterms.modified" title="W3CDTF" content="2017-04-26"/>
	
	
		<meta name="dcterms.audience" content="general public"/>
	
	
		<meta name="dcterms.spatial" content="Canada"/>
	
	
		<meta name="dcterms.type" content="guidance;notices"/>
	
	
	
	
	
		<meta name="dcterms.identifier" content="Health_Canada"/>
	
	
	
        



	<meta prefix="fb: https://www.facebook.com/2008/fbml" property="fb:pages" content="378967748836213, 160339344047502, 184605778338568, 237796269600506, 10860597051, 14498271095, 209857686718, 160504807323251, 111156792247197, 113429762015861, 502566449790031, 312292485564363, 1471831713076413, 22724568071, 17294463927, 1442463402719857, 247990812241506, 730097607131117, 1142481292546228, 1765602380419601, 131514060764735, 307780276294187, 427238637642566, 525934210910141, 1016214671785090, 192657607776229, 586856208161152, 1146080748799944, 408143085978521, 490290084411688, 163828286987751, 565688503775086, 460123390028, 318424514044, 632493333805962, 370233926766473, 173004244677, 1562729973959056, 362400293941960, 769857139754987, 167891083224996, 466882737009651, 126404198009505, 135409166525475, 664638680273646, 169011506491295, 217171551640146, 182842831756930, 1464645710444681, 218822426028, 218740415905, 123326971154939, 125058490980757, 1062292210514762, 1768389106741505, 310939332270090, 285960408117397, 985916134909087, 655533774808209, 1522633664630497, 686814348097821, 230798677012118, 320520588000085, 103201203106202, 273375356172196, 61263506236, 353102841161, 1061339807224729, 1090791104267764, 395867780593657, 1597876400459657, 388427768185631, 937815283021844, 207409132619743, 1952090675003143, 206529629372368, 218566908564369, 175257766291975, 118472908172897, 767088219985590, 478573952173735, 465264530180856, 317418191615817, 428040827230778, 222493134493922, 196833853688656, 194633827256676, 252002641498535, 398018420213195, 265626156847421, 202442683196210, 384350631577399, 385499078129720, 178433945604162, 398240836869162, 326182960762584, 354672164565195, 375081249171867, 333050716732105, 118996871563050, 240349086055056, 119579301504003, 185184131584797, 333647780005544, 306255172770146, 369589566399283, 117461228379000, 349774478396157, 201995959908210, 307017162692056, 145928592172074, 122656527842056">


	


    


	<script src="../../../../../../../assets.adobedtm.com/be5dfd287373/abb618326704/launch-3eac5e076135.min.js"></script>










<link rel="stylesheet" href="../../../../../../../use.fontawesome.com/releases/v5.15.4/css/all.css" integrity="sha256-mUZM63G8m73Mcidfrv5E+Y61y7a12O5mW4ezU3bxqW4=" crossorigin="anonymous"/>
<link rel="stylesheet" href="../../../../../../etc/designs/canada/wet-boew/css/theme.min.css"/>
<link href="https://www.canada.ca/etc/designs/canada/wet-boew/assets/favicon.ico" rel="icon" type="image/x-icon"/>
<noscript><link rel="stylesheet" href="../../../../../../etc/designs/canada/wet-boew/css/noscript.min.css"/></noscript>







                              <script>!function(a){var e="https://s.go-mpulse.net/boomerang/",t="addEventListener";if("False"=="True")a.BOOMR_config=a.BOOMR_config||{},a.BOOMR_config.PageParams=a.BOOMR_config.PageParams||{},a.BOOMR_config.PageParams.pci=!0,e="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="KBFUZ-C9D7G-RB8SX-GRGEN-HGMC9",function(){function n(e){a.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!a.BOOMR||!a.BOOMR.version&&!a.BOOMR.snippetExecuted){a.BOOMR=a.BOOMR||{},a.BOOMR.snippetExecuted=!0;var i,_,o,r=document.createElement("iframe");if(a[t])a[t]("load",n,!1);else if(a.attachEvent)a.attachEvent("onload",n);r.src="javascript:void(0)",r.title="",r.role="presentation",(r.frameElement||r).style.cssText="width:0;height:0;border:0;display:none;",o=document.getElementsByTagName("script")[0],o.parentNode.insertBefore(r,o);try{_=r.contentWindow.document}catch(O){i=document.domain,r.src="javascript:var d=document.open();d.domain='"+i+"';void(0);",_=r.contentWindow.document}_.open()._l=function(){var a=this.createElement("script");if(i)this.domain=i;a.id="boomr-if-as",a.src=e+"KBFUZ-C9D7G-RB8SX-GRGEN-HGMC9",BOOMR_lstart=(new Date).getTime(),this.body.appendChild(a)},_.write("<bo"+'dy onload="document._l();">'),_.close()}}(),"".length>0)if(a&&"performance"in a&&a.performance&&"function"==typeof a.performance.setResourceTimingBufferSize)a.performance.setResourceTimingBufferSize();!function(){if(BOOMR=a.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var e=""=="true"?1:0,t="",n="jihjtrvydlamaz7oxdea-f-fcbf34ef8-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,_={"ak.v":"39","ak.cp":"780901","ak.ai":parseInt("231651",10),"ak.ol":"0","ak.cr":2,"ak.ipv":4,"ak.proto":"http/1.1","ak.rid":"bc774bb","ak.r":47855,"ak.a2":e,"ak.m":"dscb","ak.n":"essl","ak.bpcip":"74.14.153.0","ak.cport":51787,"ak.gh":"23.42.150.4","ak.quicv":"","ak.tlsv":"tls1.2","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"reno","ak.t":"1743698120","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==nsS0m9dyyr3vdZPNb/ua3zxUl6ouQ3wYBk1B2/HxkbrI5iV7+OQwPQghv9yuDvTeNzCxhfauSNT7ATmbZa0J29yWdhqxfg+X21boDDtztSOQvEsb2FFxKuUz93RbvQO29gsbxpe7pfZmErv6FALBHdTQDucGMlwFrMsNzdw4RYTR3zrW8gLR1tl862PRe4QjKKKyn7tNoOEMF+7rpXZ83DaxVV62Jb0ZlNoj609xYvxPfQ+OEHCoUx8FmM7ItFzvzicTBGbvB+0sJuC+zb3agmAkpqWm14lLhSxwif6ocJcys2119gzVecnroe+/+p2EBzcxZ9Il1/vQFuoAlXlfxX/LPxzoT6gS+6wvnaoCQh4yuRNxCp13aaNgdys5vEHCgKDe2c1vrLVcs1b4nmfBOQeMEXG5y+Zq9ysgCs7vw4M=","ak.pv":"794","ak.dpoabenc":"","ak.tf":i};if(""!==t)_["ak.ruds"]=t;var o={i:!1,av:function(e){var t="http.initiator";if(e&&(!e[t]||"spa_hard"===e[t]))_["ak.feo"]=void 0!==a.aFeoApplied?1:0,BOOMR.addVar(_)},rv:function(){var a=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","https://www.canada.ca/en/errors/404.html","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","https://www.canada.ca/en/errors/404.html","ak.tf"];BOOMR.removeVar(a)}};BOOMR.plugins.AK={akVars:_,akDNSPreFetchDomain:n,init:function(){if(!o.i){var a=BOOMR.subscribe;a("before_beacon",o.av,null,null),a("onbeacon",o.rv,null,null),o.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script></head>

<body vocab="http://schema.org/" typeof="WebPage" resource="#wb-webpage">

    




    
        
        
        <div class="newpar new section">

</div>

    
        
        
        <div class="par iparys_inherited">

    
    
    
    
        
        
        <div class="global-header"><nav><ul id="wb-tphp">
	<li class="wb-slc"><a class="wb-sl" href="#wb-cont">Skip to main content</a></li>
	<li class="wb-slc"><a class="wb-sl" href="#wb-info">Skip to &#34;About government&#34;</a></li>
	<li class="wb-slc"><a class="wb-sl" href="#wb-sec">Skip to section menu</a></li>
</ul></nav>

<header>
	<div id="wb-bnr" class="container">
		<div class="row">
			
			<section id="wb-lng" class="col-xs-3 col-sm-12 pull-right text-right">
    <h2 class="wb-inv">Language selection</h2>
    <div class="row">
        <div class="col-md-12">
            <ul class="list-inline mrgn-bttm-0">
                <li>
                    <a lang="fr" href="https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/participation-public-consultations/conformite-application-loi/avis-intervenants-publication-documents-orientation-fins-consultation-divers-documents-orientation-bonnes-pratiques-fabrication-octroi-licences.html">
                        
                            <span class="hidden-xs" translate="no">Fran&ccedil;ais</span>
                            <abbr title="Fran&ccedil;ais" class="visible-xs h3 mrgn-tp-sm mrgn-bttm-0 text-uppercase" translate="no">fr</abbr>
                        
                        
                    </a>
                </li>
                
                
            </ul>
        </div>
    </div>
</section>
				<div class="brand col-xs-9 col-sm-5 col-md-4" property="publisher" resource="#wb-publisher" typeof="GovernmentOrganization">
					
                    
					
						
						<a href="https://www.canada.ca/en.html" property="url">
							<img src="https://www.canada.ca/etc/designs/canada/wet-boew/assets/sig-blk-en.svg" alt="Government of Canada" property="logo"/>
							<span class="wb-inv"> /
								
								<span lang="fr">Gouvernement du Canada</span>
							</span>
						</a>
					
					<meta property="name" content="Government of Canada"/>
					<meta property="areaServed" typeof="Country" content="Canada"/>
					<link property="logo" href="https://www.canada.ca/etc/designs/canada/wet-boew/assets/wmms-blk.svg"/>
				</div>
				<section id="wb-srch" class="col-lg-offset-4 col-md-offset-4 col-sm-offset-2 col-xs-12 col-sm-5 col-md-4">
					<h2>Search</h2>
					
<form action="https://www.canada.ca/en/sr/srb.html" method="get" name="cse-search-box" role="search">
	<div class="form-group wb-srch-qry">
		<label for="wb-srch-q" class="wb-inv">Search Canada.ca</label>
		
			<input id="wb-srch-q" list="wb-srch-q-ac" class="wb-srch-q form-control" name="q" type="search" value="" size="34" maxlength="170" placeholder="Search Canada.ca"/>
		    
		

		<datalist id="wb-srch-q-ac">
		</datalist>
	</div>
	<div class="form-group submit">
	<button type="submit" id="wb-srch-sub" class="btn btn-primary btn-small" name="wb-srch-sub"><span class="glyphicon-search glyphicon"></span><span class="wb-inv">Search</span></button>
	</div>
</form>

				</section>
		</div>
	</div>
	<hr/>
	
	<div class="container"><div class="row">
		
        <div class="col-md-8">
        <nav class="gcweb-menu" typeof="SiteNavigationElement">
		<h2 class="wb-inv">Menu</h2>
		<button type="button" aria-haspopup="true" aria-expanded="false"><span class="wb-inv">Main </span>Menu <span class="expicon glyphicon glyphicon-chevron-down"></span></button>
<ul role="menu" aria-orientation="vertical" data-ajax-replace="/content/dam/canada/sitemenu/sitemenu-v2-en.html">
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/jobs.html">Jobs and the workplace</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/immigration-citizenship.html">Immigration and citizenship</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://travel.gc.ca/">Travel and tourism</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/business.html">Business and industry</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/benefits.html">Benefits</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/health.html">Health</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/taxes.html">Taxes</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/environment.html">Environment and natural resources</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/defence.html">National security and defence</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/culture.html">Culture, history and sport</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/policing.html">Policing, justice and emergencies</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/transport.html">Transport and infrastructure</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.international.gc.ca/world-monde/index.aspx?lang=eng">Canada and the world</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/finance.html">Money and finances</a></li>
	<li role="presentation"><a role="menuitem" tabindex="-1" href="https://www.canada.ca/en/services/science.html">Science and innovation</a></li>
</ul>

		
        </nav>   
        </div>
		
		
		
    </div></div>
	
		<nav id="wb-bc" property="breadcrumb"><h2 class="wb-inv">You are here:</h2><div class="container"><ol class="breadcrumb">
<li><a href='https://www.canada.ca/en.html'>Canada.ca</a></li>
<li><a href='https://www.canada.ca/en/government/dept.html'>Departments and agencies</a></li>
<li><a href='https://www.canada.ca/en/health-canada.html'>Health Canada</a></li>
<li><a href='../../../drugs-health-products.html'>Drugs and health products</a></li>
<li><a href='../../public-involvement-consultations.html'>Public Involvement and Consultations</a></li>
<li><a href='../compliance-enforcement.html'>Compliance and Enforcement</a></li>
</ol></div></nav>


	

  
</header>
</div>

    

</div>

    




	









<div class="container">
    <div class="row">
        <main property="mainContentOfPage" resource="#wb-main" typeof="WebPageElement" class="col-md-9 col-md-push-3">
            

    <h1 property="name" id="wb-cont" dir="ltr">
Notice to Stakeholders –Release of Guidance Documents for Consultation: Various good manufacturing practices and drug establishment licensing guidance documents</h1>




                 
                    <div><div class="mwsbodytext text parbase section">
    

    
        <a id="cont" name="cont"></a>
    


</div>
<div class="mwsalerts section">


	
		


	

<section class="alert borderRed alert alert-danger">
	<h3> </h3>
	<p>The consultation is now closed. This page is a snapshot of the consultation as it was presented to the public. The new guidance documents will be posted once finalized.</p>
</section>



	

</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>January 18, 2017</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Health Canada is pleased to announce the release of the following draft guidance documents for a 90&nbsp;day stakeholder consultation from January&nbsp;18, 2017 to April&nbsp;18, 2017:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li><span class="noWrap">GUI-0001:</span> Good manufacturing practices guide for drug products</li> 
 <li><span class="noWrap">GUI-0023:</span> Risk classification guide for drug good manufacturing practices observations</li> 
 <li><span class="noWrap">GUI-0031:</span> Good manufacturing practices for medical gases</li> 
 <li><span class="noWrap">GUI-0080:</span> How to demonstrate foreign building compliance with drug good manufacturing practices</li> 
 <li><span class="noWrap">GUI-0119:</span> Annex&nbsp;1 to the Good manufacturing practices guide <em>–</em> Manufacture of sterile drugs</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>These revised guidance documents contain new information. Plain language principles to make the documents easier to read and understand have been considered in rewriting and formatting the documents. They will continue to support compliance with good manufacturing practices and drug establishment licence requirements prescribed in Part&nbsp;C, Division&nbsp;1A and Division&nbsp;2 of the <em>Food and Drug Regulations</em> (FDR).</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>The key changes to the documents are listed below.</p>
    


</div>
<div class="mwstext section"><div class="clearfix"></div></div>
<div class="mwsbodytext text parbase section">
    

    
        <h2>How to participate</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h3>1. Obtain documents</h3>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Please email <a class="noWrap" href="mailto:HPIL-Consultation-IPSOP@hc-sc.gc.ca">HPIL-Consultation-IPSOP@hc-sc.gc.ca</a> to receive copies of:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>each draft guidance document, and</li> 
 <li>the comment form for your submission of comments by section number and line number.</li> 
</ul>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <h3>2. Submit comments</h3>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Please email your comments to <a class="noWrap" href="mailto:HPIL-Consultation-IPSOP@hc-sc.gc.ca">HPIL-Consultation-IPSOP@hc-sc.gc.ca</a> using one comment form for each guidance document. All comments will be considered in the finalization of the documents. The <span class="noWrap">90-day</span> consultation period is from January&nbsp;18, 2017 to April&nbsp;18, 2017 inclusive.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Comments can also be mailed to:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Health Product Inspection and Licensing Division<br> Health Product Compliance Directorate<br> 13th&nbsp;Floor, Jeanne Mance Building<br> 200 Eglantine Driveway, Tunney's Pasture<br> Address Locator #&nbsp;1913D<br> Ottawa Ontario K1A&nbsp;0K9</p>
    


</div>
<div class="mwstext section"><div class="clearfix"></div></div>
<div class="mwsbodytext text parbase section">
    

    
        <h2>Overview of Key Changes</h2>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>The Health Canada guidance documents have been rewritten and formatted using plain language principles to make the documents easier to read and understand. This is in conformance with requirements for migration of documents to the Canada.ca website. As an exception, international content proposed for direct adoption in <span class="noWrap">GUI-0119:</span> Annex&nbsp;1 to the Good manufacturing practices guide&nbsp;<em>–</em> Manufacture of sterile drugs has been retained as originally written.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p><em><span class="noWrap">GUI-0001</span> Good manufacturing practices (GMP) guide for drug products</em> is applicable to all fabricators, packagers/labelers, testers, importers, distributors and wholesalers who work with drugs. Changes include:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>New guidance to address emerging issues such as data integrity, and to address new regulations pertaining to active pharmaceutical ingredients (API).</li> 
 <li>Enhanced responsibilities for importers of products from non-MRA countries with new requirement to conduct audits of foreign buildings and increased retesting requirements on imported products.</li> 
 <li>Removal of guidance under the sterile products section <span class="noWrap">(C.02.029)</span> and replace it with guidance published by the Pharmaceutical Inspection Cooperation Scheme (PIC/S). The documents to be adopted are "Guide to Good Manufacturing Practice for Medicinal Products Annexes - Annex&nbsp;1 - Manufacture of sterile medicinal products" <span class="noWrap">(PE 009-12 -</span> <span class="noWrap">1 October 2015)</span> and "GMP Annex&nbsp;1 Revision&nbsp;2008, Interpretation of Most Important Changes For The Manufacture of Sterile Medicinal Products" <span class="noWrap">(PI 032-2 <em>–</em></span> <span class="noWrap">8 January 2010).</span> Health Canada is proposing to adopt this international guidance to enable easier updating of sterile products guidance and facilitate international harmonization. The adopted sterile products guidance is presented in a new document entitled "Annex&nbsp;1 to the good manufacturing practices guide <em>–</em> Manufacture of sterile drugs <span class="noWrap">(GUI-0119).</span></li> 
 <li>Incorporation of <a href="../../compliance-enforcement/good-manufacturing-practices/questions-answers/good-manufacturing-practices-questions-answers.html">GMP Questions and Answers</a> into the guidance, where appropriate, and introduction of a Q&amp;A section in the appendices. The content of the guidance document "<a href="../../compliance-enforcement/good-manufacturing-practices/validation/validation-documentation-requirements-responsibilities-drug-fabricators-packagers-labe">Validation documentation requirements and responsibilities for Drug Fabricators, Packagers/Labellers, Testers, Distributors and Importers</a>" <span class="noWrap">(GUI-0042)</span> was also incorporated. We propose to remove the existing GMP Q&amp;A document and <span class="noWrap">GUI-0042</span> from the Health Canada website upon approval of this revised <span class="noWrap">GUI-0001.</span></li> 
</ul>
    


</div>
<div class="mwstext section"><div class="clearfix"></div></div>
<div class="mwsbodytext text parbase section">
    

    
        <p><em><span class="noWrap">GUI-0023:</span> Risk classification guide for drug good manufacturing practices observations</em> is applicable to all fabricators, packagers/labelers, testers, importers, distributors and wholesalers who work with drugs. Changes include:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>Expanded scope to include on site inspections of domestic and foreign buildings (finished dosage form as well as API sites). It also includes Health Canada's assessment of GMP evidence to ensure the information submitted by importers demonstrates the foreign building's compliance with Division&nbsp;2 of the FDR.</li> 
 <li>New sample observations to reflect updated additional requirements introduced into two guidance documents being posted for consultation at the same time <em>–</em> Good manufacturing practices guide for drug products <span class="noWrap">(GUI-0001)</span> and Annex&nbsp;1 to the good manufacturing practices guide <em>–</em> Manufacture of sterile drug products <span class="noWrap">(GUI-0119).</span> The new observations cover new regulatory requirements such as for APIs, and emerging issues such as data integrity.</li> 
</ul>
    


</div>
<div class="mwstext section"><div class="clearfix"></div></div>
<div class="mwsbodytext text parbase section">
    

    
        <p><em><span class="noWrap">GUI-0031:</span> Good manufacturing practices for medical gases</em> is applicable to all fabricators, packagers/labelers, testers, importers, distributors, wholesalers and home care providers who work with medical gases. Changes include:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>Questions and answers (Q&amp;As) from <a href="../../compliance-enforcement/good-manufacturing-practices/questions-answers/medical-gas-good-manufacturing-practices-questions-answers.html">Medical Gas - Good Manufacturing Practices (GMP) Questions and Answers</a> were incorporated into the main guidance, where appropriate. Specific Q&amp;As are listed as an appendix. In future, it is proposed that Q&amp;As be maintained as an appendix to this document.</li> 
 <li>New regulations and revised definition for wholesaler was included to reflect changes to the FDR resulting from the coming into force of regulations pertaining to APIs.</li> 
 <li>Chapter&nbsp;4 on quality management was updated to reflect changes made to <span class="noWrap">GUI-0001</span> (to harmonize internationally). Changes include reference to concepts of quality risk management and quality management throughout product lifecycle, with reference to ICH&nbsp;Q10.</li> 
 <li>New or expanded rationale and interpretations in chapter 5 respecting senior management responsibilities, deviations and non-conformances, accuracy and reliability of data and records, and records expectations.</li> 
</ul>
    


</div>
<div class="mwstext section"><div class="clearfix"></div></div>
<div class="mwsbodytext text parbase section">
    

    
        <p><em><span class="noWrap">GUI-0080:</span> How to demonstrate foreign building compliance with drug good manufacturing practices</em> is applicable to all Canadian importers who work with drugs. Changes include:</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>Incorporation of information with respect to foreign buildings that fabricate, package, label or test <span class="noWrap">non-sterile</span> APIs.</li> 
 <li>Incorporation of the <em>new evidence required by date</em> to replace the expiry date on a drug establishment license and details on the implications.</li> 
 <li>Clarification on filing requirements, processing and Health Canada's assessment.</li> 
 <li>Revised evidence requirements for foreign buildings that fabricate, package, label or test finished dosage forms or APIs.</li> 
 <li>Incorporation of Questions and Answers into the guidance, where appropriate, and introduction of a Q&amp;A section in the appendices.</li> 
</ul>
    


</div>
<div class="mwstext section"><div class="clearfix"></div></div>
<div class="mwsbodytext text parbase section">
    

    
        <p><em><span class="noWrap">GUI-0119:</span> Annex&nbsp;1 to the Good manufacturing practices guide – Manufacture of sterile drugs</em> is applicable to all fabricators, packagers/labelers, testers, importers, and distributors who work with sterile drugs.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <p>Health Canada is seeking feedback on a proposal to adopt the international GMP guidance published by the Pharmaceutical Inspection Cooperation Scheme (PIC/S) as described in the proposed Health Canada guide.</p>
    


</div>
<div class="mwsbodytext text parbase section">
    

    
        <ul> 
 <li>The PIC/S documents proposed to be adopted by Health Canada in <span class="noWrap">GUI-0119</span> are "Guide to Good Manufacturing Practice for Medicinal Products Annexes - Annex&nbsp;1 -Manufacture of sterile medicinal products" <span class="noWrap">(PE 009-12 -</span> <span class="noWrap">1 October 2015)</span> and "GMP Annex&nbsp;1 Revision 2008, Interpretation of Most Important Changes For The Manufacture of Sterile Medicinal Products" <span class="noWrap">(PI 032-2 <em>–</em></span> <span class="noWrap">8 January 2010).</span></li> 
 <li>The PIC/S documents are currently being revised under a joint initiative that includes Health Canada.</li> 
 <li>A consultation with Canadian stakeholders on the content of the upcoming revision to the PIC/S GMP Annex&nbsp;1 is anticipated in the first half of 2017.</li> 
 <li>Under this proposal, Health Canada will remove guidance currently published under the sterile products section <span class="noWrap">(C.02.029)</span> of "Good Manufacturing Practices (GMP) Guidelines <em>–</em> 2009&nbsp;Edition, Version&nbsp;2 <span class="noWrap">(GUI-0001)"</span> and replace it with guidance published by the PIC/S as Health Canada <span class="noWrap">GUI-0119.</span></li> 
 <li>The adoption of these PIC/S documents for the manufacture of sterile drugs is intended to facilitate increased international harmonization. The interpretations in the PIC/S documents are to be adopted verbatim in this guide.</li> 
 <li>Health Canada's <a href="../../compliance-enforcement/good-manufacturing-practices/questions-answers/good-manufacturing-practices-questions-answers.html#sterile">GMP Questions and Answers</a> pertaining to sterile drugs will be incorporated in a Q&amp;A section in the appendices of <span class="noWrap">GUI-0119.</span> We propose to remove the existing document entitled "Good Manufacturing Practices Questions and Answers" from the Health Canada website upon approval of the revised <span class="noWrap">GUI-0001</span> and <span class="noWrap">GUI-0119.</span></li> 
 <li>Health Canada plans to rename the current "<a href="../../compliance-enforcement/good-manufacturing-practices/guidance-documents/annex-1-current-edition-selected-category-monograph-drugs-0066.html">Annex&nbsp;1 to the Current Edition of the Good Manufacturing Practices Guidelines - Selected Category IV Monograph Drugs</a>" <span class="noWrap">(GUI-0066)</span> to an alternate Annex number upon its next revision.</li> 
</ul>
    


</div>
<div class="mwstext section"><div class="clearfix"></div></div>

</div>
                
            <section class="pagedetails">
    <h2 class="wb-inv">Page details</h2>
    
        <dl id="wb-dtmd">
    <dt>Date modified:</dt>
    <dd><time property="dateModified">2017-04-26</time></dd>
</dl>
</section>

        </main>
        <nav class="wb-sec col-md-3 col-md-pull-9" typeof="SiteNavigationElement" id="wb-sec">
            <div>
    <h2 id="wb-sec-h" class="wb-inv">Section Menu</h2>
    <section class="list-group menu list-unstyled">
        <h3 class="wb-navcurr"><a href="../compliance-enforcement.html">Compliance and Enforcement</a></h3>
        <ul class="list-group menu list-unstyled">
            <li><a href="consultation-summary-notice-stakeholders-atypical-active-pharmaceutical-ingredients.1584.dela" class="list-group-item">Consultation Summary: Notice to Stakeholders - Implementation of Establishment Licensing Requirements for Atypical Active Pharmaceutical Ingredients</a>
                
            </li>
        
            <li><a href="good-manufacturing-practices-guidelines-2009-edition-0001.html" class="list-group-item">ARCHIVED - Good Manufacturing Practices (GMP) Guidelines - 2009 Edition (GUI-0001)</a>
                
            </li>
        
            <li><a href="creation-regulatory-framework-implementation-good-manufacturing-practices-active.html" class="list-group-item">Creation of a Regulatory Framework for the Implementation of Good Manufacturing Practices for Active Pharmaceutical Ingredients (API) - 2009 Health Canada Consultation Notice</a>
                
            </li>
        
            <li><a href="creation-regulatory-framework-implementation-good-manufacturing-practices-active-pharmaceutic" class="list-group-item">Creation of a Regulatory Framework for the Implementation of Good Manufacturing Practices for Active Pharmaceutical Ingredients (API) - 2009 Health Canada Consultation Document</a>
                
            </li>
        
            <li><a href="drug-establishments-reviewing-good-manufacturing-practices-inspection-program.html" class="list-group-item">ARCHIVED - Drug Establishments: Reviewing the Good Manufacturing Practices Inspection Program</a>
                
            </li>
        
            <li><a href="good-manufacturing-practices-program-review.html" class="list-group-item">ARCHIVED - Consultation on Good Manufacturing Practices - Program Review</a>
                
            </li>
        
            <li><a href="draft-guide-risk-classification-observations-made-inspections-blood-establishments.1582.delay" class="list-group-item">ARCHIVED - Consultation: Draft Guide for the Risk Classification of Observations Made During Inspections of Blood Establishments (Revised)</a>
                
            </li>
        
            <li><a href="draft-documents-drug-good-manufacturing-practices-inspection-program-0001-related.1581.delaye" class="list-group-item">ARCHIVED - Consultation: Draft Documents for Drug Good Manufacturing Practices (GMP) Inspection Program (GUI-0001 Related)</a>
                
            </li>
        
            <li><a href="regulations-amending-food-drug-regulations-1447.html" class="list-group-item">ARCHIVED - Consultation: Regulations Amending the Food and Drug Regulations 1447 - Good Manufacturing Practices</a>
                
            </li>
        
            <li><a href="regulations-amending-food-drug-regulations-1447-good-manufacturing-practices-2009.1587.delaye" class="list-group-item">ARCHIVED - Avis : Consultation: Regulations Amending the Food and Drug Regulations 1447 - Good Manufacturing Practices</a>
                
            </li>
        
            <li><a href="good-manufacturing-practices-guidelines-2010-consultation-registration-form.html" class="list-group-item">ARCHIVED - Good Manufacturing Practices (GMP)/Establishment Licence (EL) Information Sessions (Registration Form)</a>
                
            </li>
        
            <li><a href="good-manufacturing-practices-guidelines-2010-consultation-notice.html" class="list-group-item">ARCHIVED - Good Manufacturing Practices (GMP) - Establishment Licence (EL) Information Sessions</a>
                
            </li>
        
            <li><a href="cleaning-validation-guidance-0028-consultation.html" class="list-group-item">Consultation: Cleaning Validation Guidance (GUI-0028)</a>
                
            </li>
        
            <li><a href="guidance-classification-observations-inspection-cells-tissues-organs-establishments-0101-cons" class="list-group-item">Draft - Guidance on Classification of Observations for Inspection of Cells, Tissues and Organs Establishments (GUI-0101)</a>
                
            </li>
        
            <li><a href="draft-guidance-good-manufacturing-practices-active-pharmaceutical-ingredients-apis-guidelines" class="list-group-item">Consultation: Draft Guidance on Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients (APIs) Guidelines (GUI-0104)</a>
                
            </li>
        
            <li><a href="survey-constituencies-input-development-question-answer-document.html" class="list-group-item">Consultation - Invitation to Participate in the Survey for ICH Q7 Constituencies: Input for Development of a Question and Answer Document</a>
                
            </li>
        
            <li><a href="notice-stakeholders-implementation-establishment-licensing-requirements-atypical-active-pharm" class="list-group-item">Notice to Stakeholders - Implementation of Establishment Licensing Requirements for Atypical Active Pharmaceutical Ingredients</a>
                
            </li>
        
            <li><a href="consultation-atypical-active-pharmaceutical-ingredients-list.html" class="list-group-item">Consultation on the Atypical Active Pharmaceutical Ingredients List</a>
                
            </li>
        
            <li><a href="consultation-draft-documents-medical-devices-program.html" class="list-group-item">Consultation: Draft Documents for Medical Devices Program</a>
                
            </li>
        
            <li><a href="notice-stakeholders-release-guidance-documents-consultation-various-good-manufacturing-practi" class="list-group-item wb-navcurr">Notice to Stakeholders –Release of Guidance Documents for Consultation: Various good manufacturing practices and drug establishment licensing guidance documents</a>
                
            </li>
        
            <li><a href="consultation-atypical-active-pharmaceutical-ingredients-veterinary-use-list.html" class="list-group-item">Consultation on the List of Atypical Active Pharmaceutical Ingredients for Veterinary Use</a>
                
            </li>
        
            <li><a href="drug-natural-health-products-recall-guide.html" class="list-group-item">Drug and natural health products recall guide consultation</a>
                
            </li>
        
            <li><a href="validation-cleaning-0028-drug-dosage-form-0029.html" class="list-group-item">Notice to stakeholders - Release of draft guidance documents for consultation: Cleaning validation guide (GUI-0028) and Guide to validating drug dosage forms (GUI-0029)</a>
                
            </li>
        
            <li><a href="manufacturing-active-pharmaceutical-ingredients-gui-0104.html" class="list-group-item">Notice to Stakeholders - Release of Good Manufacturing Practices for Active Pharmaceutical Ingredients (GUI-0104) for Consultation</a>
                
            </li>
        
            <li><a href="environmental-control-drugs-storage-transportation-gui-0069.html" class="list-group-item">Notice to stakeholders - Release of draft guidance document for consultation: Guidelines for environmental control of drugs during storage and transportation (GUI-0069)</a>
                
            </li>
        
            <li><a href="draft-guidance-annex-4-good-manufacturing-practices-guide-veterinary-drugs.html" class="list-group-item">Notice to stakeholders – Release of draft guidance document for consultation: Annex 4 to the Good manufacturing practices guide – Veterinary drugs</a>
                
            </li>
        
            <li><a href="notice-draft-guide-manufacturing-medicinal-products-annex-1.html" class="list-group-item">Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good Manufacturing Practice for Medicinal Products Annex 1 Manufacture of Sterile Medicinal Products - 3-month consultation period</a>
                
            </li>
        
            <li><a href="notice-draft-guidance-consultation-annex-3a-good-manufacturing-practices-schedule-c-drugs.156" class="list-group-item">Notice to stakeholders – Release of draft guidance document for consultation: Annex 3A to the Good Manufacturing Practices Guide</a>
                
            </li>
        </ul>
    </section>
 <!-- comment --></div>
        </nav>
    </div>
</div>





    




    
        
        
        <div class="newpar new section">

</div>

    
        
        
        <div class="par iparys_inherited">

    
    
    
    

</div>

    




    




    
        
        
        <div class="newpar new section">

</div>

    
        
        
        <div class="par iparys_inherited">

    
    
    
    
        
        
        <div class="global-footer">
    <footer id="wb-info">
	    <h2 class="wb-inv">About this site</h2>
    	<div class="gc-contextual"><div class="container">
    <nav>
        <h3>Health Canada</h3>
        <ul class="list-col-xs-1 list-col-sm-2 list-col-md-3">
            <li><a href="https://www.canada.ca/en/health-canada/corporate/contact-us.html">Contact us</a></li>
        </ul>
    </nav>
</div></div>	
        <div class="gc-main-footer">
			<div class="container">
	<nav>
	<h3>Government of Canada</h3>
	<ul class="list-unstyled colcount-sm-2 colcount-md-3">
		<li><a href="https://www.canada.ca/en/contact.html">All contacts</a></li>
		<li><a href="https://www.canada.ca/en/government/dept.html">Departments and agencies</a></li>
		<li><a href="https://www.canada.ca/en/government/system.html">About government</a></li>
	</ul>
	<h4><span class="wb-inv">Themes and topics</span></h4>
	<ul class="list-unstyled colcount-sm-2 colcount-md-3">			
		<li><a href="https://www.canada.ca/en/services/jobs.html">Jobs</a></li>
		<li><a href="https://www.canada.ca/en/services/immigration-citizenship.html">Immigration and citizenship</a></li>
		<li><a href="https://travel.gc.ca/">Travel and tourism</a></li>
		<li><a href="https://www.canada.ca/en/services/business.html">Business</a></li>
		<li><a href="https://www.canada.ca/en/services/benefits.html">Benefits</a></li>
		<li><a href="https://www.canada.ca/en/services/health.html">Health</a></li>
		<li><a href="https://www.canada.ca/en/services/taxes.html">Taxes</a></li>
		<li><a href="https://www.canada.ca/en/services/environment.html">Environment and natural resources</a></li>
		<li><a href="https://www.canada.ca/en/services/defence.html">National security and defence</a></li>
		<li><a href="https://www.canada.ca/en/services/culture.html">Culture, history and sport</a></li>
		<li><a href="https://www.canada.ca/en/services/policing.html">Policing, justice and emergencies</a></li>
		<li><a href="https://www.canada.ca/en/services/transport.html">Transport and infrastructure</a></li>
		<li><a href="https://www.international.gc.ca/world-monde/index.aspx?lang=eng">Canada and the world</a></li>
		<li><a href="https://www.canada.ca/en/services/finance.html">Money and finances</a></li>
		<li><a href="https://www.canada.ca/en/services/science.html">Science and innovation</a></li>
		<li><a href="https://www.canada.ca/en/services/indigenous-peoples.html">Indigenous Peoples</a></li>
		<li><a href="https://www.canada.ca/en/services/veterans-military.html">Veterans and military</a></li>
		<li><a href="https://www.canada.ca/en/services/youth.html">Youth</a></li>
	</ul>
	</nav>
</div>
	
        </div>
        <div class="gc-sub-footer">
            <div class="container d-flex align-items-center">
            <nav>
                <h3 class="wb-inv">Government of Canada Corporate</h3>
                <ul>
                
                    		<li><a href="https://www.canada.ca/en/social.html">Social media</a></li>
		<li><a href="https://www.canada.ca/en/mobile.html">Mobile applications</a></li>
		<li><a href="https://www.canada.ca/en/government/about.html">About Canada.ca</a></li>
                
                <li><a href="https://www.canada.ca/en/transparency/terms.html">Terms and conditions</a></li>
                <li><a href="https://www.canada.ca/en/transparency/privacy.html">Privacy</a></li>
                </ul>
            </nav>
                <div class="wtrmrk align-self-end">
                    <img src="https://www.canada.ca/etc/designs/canada/wet-boew/assets/wmms-blk.svg" alt="Symbol of the Government of Canada"/>
                </div>
            </div>
        </div>
    </footer>

</div>

    

</div>

    




    







    <script type="text/javascript">_satellite.pageBottom();</script>






<script src="../../../../../../../ajax.googleapis.com/ajax/libs/jquery/2.2.4/jquery.min.js" integrity="sha256-BbhdlvQf/xTY9gja0Dq3HiwQF8LaCRTXxZKRutelT44=" crossorigin="anonymous"></script>
<script src="../../../../../../etc/designs/canada/wet-boew/js/ep-pp.min.js"></script>
<script src="../../../../../../etc/designs/canada/wet-boew/js/wet-boew.min.js"></script>
<script src="../../../../../../etc/designs/canada/wet-boew/js/theme.min.js"></script>




</body>

<!-- Mirrored from www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/compliance-enforcement/notice-stakeholders-release-guidance-documents-consultation-various-good-manufacturing-practices-drug-establishment-licensing-guidance-documents.html by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 03 Apr 2025 21:44:52 GMT -->
</html>
